Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,485 active trials253 approved drugs3,567 evidence items
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,566 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03789604 | A Study of CS1001 in Subjects With Stage IV Non-Small Cell Lung Cancer | completed | Phase 3 | 479 | CStone PharmaceuticalsINDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT00433706 | Image Guided Radiation Therapy For Prostate Cancer | completed | Phase 3 | 470 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| Standard Neoadjuvant Chemotherapy Versus Genomic Driven Chemotherapy in Patients With Breast Cancer(REMAGUS04) |
| completed |
| Phase 3 |
| 303 |
| Gustave Roussy, Cancer Campus, Grand ParisOTHER |
| 1 |
| Aug 17, 2026 |
| clinicaltrials |
| NCT00974948 | Trial of Endoscopic Ultrasound (EUS) - Guided Celiac Plexus Neurolysis | completed | Phase 3 | 100 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT04173533 | Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT(AMADEUS) | completed | Phase 3 | 326 | University of BirminghamOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT06490328 | Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer | completed | Phase 3 | 161 | Dongkook Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 14, 2026 | clinicaltrials |
| NCT07764653 | Technetium Tc 99m Sulfur Colloid Injection for Tracing Sentinel Nodes in Breast Cancer | completed | Phase 3 | 213 | HTA Co., Ltd.INDUSTRY | 1 | Aug 14, 2026 | clinicaltrials |
| NCT00770809 | Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery | completed | Phase 3 | 305 | National Cancer Institute (NCI)NIH | 2 | Aug 12, 2026 | clinicaltrials |
| NCT04939142 | A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)(BENCH) | completed | Phase 3 | 154 | Antengene CorporationINDUSTRY | 1 | Aug 10, 2026 | clinicaltrials |
| NCT00265850 | Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer | completed | Phase 3 | 2,334 | Alliance for Clinical Trials in OncologyOTHER | 2 | Aug 7, 2026 | clinicaltrials |
| NCT02761070 | Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III(RE-GEND) | completed | Phase 3 | 146 | Kyorin UniversityOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT01547741 | Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer | completed | Phase 3 | 4,242 | NSABP Foundation IncNETWORK | 2 | Aug 6, 2026 | clinicaltrials |
| NCT03924050 | Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKI | completed | Phase 3 | 440 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT02101788 | Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer | completed | Phase 2 / Phase 3 | 260 | National Cancer Institute (NCI)NIH | 2 | Aug 4, 2026 | clinicaltrials |
| NCT05184088 | Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis(CArdiag) | completed | Phase 3 | 244 | Lantheus Germany GmbHINDUSTRY | 4 | Aug 3, 2026 | clinicaltrials |
| NCT01503632 | Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission | completed | Phase 3 | 570 | Children's Oncology GroupNETWORK | 2 | Jul 31, 2026 | clinicaltrials |
| NCT00400946 | 05-001: Treatment of Acute Lymphoblastic Leukemia in Children | completed | Phase 3 | 800 | Dana-Farber Cancer InstituteOTHER | 2 | Jul 30, 2026 | clinicaltrials |
| NCT07590505 | Ultrahypofractionated Versus Normofractionated Sequential Boost After Whole-breast Radiation Therapy in Patients Treated With Breast-conserving Surgery for Breast Cancer(ULTIMO) | completed | Phase 3 | 132 | Cancer Research AntwerpOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT00379340 | Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor | completed | Phase 3 | 395 | Children's Oncology GroupNETWORK | 7 | Jul 24, 2026 | clinicaltrials |
| NCT03223753 | Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer | completed | Phase 3 | 299 | Children's Oncology GroupNETWORK | 2 | Jul 24, 2026 | clinicaltrials |
| NCT04158440 | Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC | completed | Phase 3 | 501 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT03924856 | Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)(KEYNOTE-866) | completed | Phase 3 | 907 | Merck Sharp & Dohme LLCINDUSTRY | 22 | Jul 22, 2026 | clinicaltrials |
| NCT04210115 | Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975) | completed | Phase 3 | 703 | Merck Sharp & Dohme LLCINDUSTRY | 27 | Jul 22, 2026 | clinicaltrials |
| NCT05198934 | Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation(CodeBreak300) | completed | Phase 3 | 160 | AmgenINDUSTRY | 12 | Jul 22, 2026 | clinicaltrials |
| NCT04702009 | Efficacy and Safety of First-line Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy and Bronchoscopy-assisted Interventional Therapy in Patients With Advanced Central Non-small Cell Lung Cancer | completed | Phase 2 / Phase 3 | 33 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT01302834 | Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer | completed | Phase 3 | 987 | Radiation Therapy Oncology GroupNETWORK | 2 | Jul 20, 2026 | clinicaltrials |
| NCT01564056 | Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment(ASTER 70s) | completed | Phase 3 | 1,989 | UNICANCEROTHER | 2 | Jul 20, 2026 | clinicaltrials |
| NCT03480360 | Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression | completed | Phase 3 | 21 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT06320353 | Study сomparing the Efficacy and Safety of RPH-075 and Keytruda® in Patients With Unresectable or Metastatic Skin Melanoma | completed | Phase 3 | 266 | R-PharmINDUSTRY | 1 | Jul 15, 2026 | clinicaltrials |
| NCT00093470 | Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission | completed | Phase 3 | 144 | National Cancer Institute (NCI)NIH | 3 | Jul 14, 2026 | clinicaltrials |
| NCT02752035 | A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy | completed | Phase 3 | 183 | Astellas Pharma Global Development, Inc.INDUSTRY | 13 | Jul 14, 2026 | clinicaltrials |
| NCT03519971 | Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer | completed | Phase 3 | 328 | AstraZenecaINDUSTRY | 14 | Jul 14, 2026 | clinicaltrials |
| NCT07435324 | A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma | completed | Phase 3 | 161 | R-PharmINDUSTRY | 2 | Jul 14, 2026 | clinicaltrials |
| NCT04723004 | Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC | completed | Phase 3 | 326 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 2 | Jul 13, 2026 | clinicaltrials |
| NCT06151197 | Study to Assess EN3835 in the Treatment of Plantar Fibromatosis (Also Known as Ledderhose Disease)(STRIDE) | completed | Phase 3 | 436 | Endo USA Inc., a Keenova Therapeutics CompanyINDUSTRY | 2 | Jul 13, 2026 | clinicaltrials |
| NCT02364557 | Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival | completed | Phase 2 / Phase 3 | 129 | NRG OncologyOTHER | 4 | Jul 10, 2026 | clinicaltrials |
| NCT02635009 | Whole-Brain Radiation Therapy With or Without Hippocampal Avoidance in Limited Stage or Extensive Stage Small Cell Lung Cancer | completed | Phase 2 / Phase 3 | 418 | NRG OncologyOTHER | 2 | Jul 10, 2026 | clinicaltrials |
| NCT03274687 | Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer | completed | Phase 3 | 296 | NRG OncologyOTHER | 3 | Jul 9, 2026 | clinicaltrials |
| NCT03879109 | Chemotherapy Followed by Pelvic Reirradiation Versus Chemotherapy Alone as Pre-operative Treatment for Locally Recurrent Rectal Cancer(GRECCAR15) | completed | Phase 3 | 58 | University Hospital, BordeauxOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT00980460 | Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer | completed | Phase 3 | 236 | National Cancer Institute (NCI)NIH | 6 | Jun 30, 2026 | clinicaltrials |
| NCT07671547 | Prophylaxis of Hematologic Complications With Naderin in First-Line Breast Cancer Chemotherapy(NADERIN-BC) | completed | Phase 2 / Phase 3 | 79 | MIPO ClinicOTHER | 0 | Jun 30, 2026 | clinicaltrials |
| NCT04248829 | Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301) | completed | Phase 3 | 393 | Yuhan CorporationINDUSTRY | 13 | Jun 29, 2026 | clinicaltrials |
| NCT05326464 | Tofacitinib in Recurrent GBM Patients | completed | Phase 3 | 18 | University of Texas Southwestern Medical CenterOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT01805076 | MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer | completed | Phase 3 | 319 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT02393859 | Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL) | completed | Phase 3 | 111 | AmgenINDUSTRY | 24 | Jun 26, 2026 | clinicaltrials |
| NCT02220894 | Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042) | completed | Phase 3 | 1,274 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 25, 2026 | clinicaltrials |
| NCT03088540 | Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 3 | 712 | Regeneron PharmaceuticalsINDUSTRY | 24 | Jun 25, 2026 | clinicaltrials |
| NCT07669506 | A Study to Evaluate the Efficacy and Safety of Orally Administered Extract of Orthosiphon Stamineus (NuvastaticTM-C5OSEW5050ESA) in Patient With Breast Cancer Undergoing Chemotherapy(NuvastaticTM) | completed | Phase 3 | 180 | Natureceuticals Sdn BhdINDUSTRY | 1 | Jun 25, 2026 | clinicaltrials |
| NCT00942331 | Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer | completed | Phase 3 | 506 | National Cancer Institute (NCI)NIH | 2 | Jun 24, 2026 | clinicaltrials |
| NCT01015833 | Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer | completed | Phase 3 | 356 | National Cancer Institute (NCI)NIH | 3 | Jun 24, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Aug 18, 2026source: clinicaltrials